Document:

Exhibit 10.1

 

	
 
    	

    
	
 
    	
 
    
	
 
    	
Carpenter Technology Corporation
    
	
 
    	
1735 Market Street, 15th Floor
    
	
 
    	
Philadelphia, PA 19103
    
	
 
    	
610-208-2136
    
			

 

 

August 6, 2018

 

Mr. Timothy F. Lain

 

Dear Tim:

 

We are pleased to extend an offer for the position of Vice President and Chief Financial Officer reporting to Tony Thene, President and Chief Executive Officer. Your work location will be Philadelphia, PA. Your effective date in this role is September 14, 2018. Highlights of your new position include:

 

·                  Annual Base Salary: $400,000.00 paid bi-weekly.

 

·                  Annual Bonus Plan: You will be eligible to participate in the Company’s Executive Bonus Compensation Plan or such successor arrangement (if any) as the Board may from time to time establish.  Your target annual bonus opportunity for the fiscal year ending June 30, 2019 is 55% of your annual base salary pro-rated based on earnings received during the fiscal year.  Zero to 200% of target will be earned based on achievement of the relevant corporate performance objectives as determined by the Board or its Compensation Committee each fiscal year.

 

·                  Long Term Incentive Grants:  The Company generally grants equity awards to its senior executives annually. The terms of these awards are determined by the Compensation Committee of Carpenter’s Board of Directors. You will be eligible to receive an annual award at the time these grants are made to all employees in similar positions, and those grants are generally administered in the first fiscal quarter of the year. The current target of the annual equity incentive for your position is $400,000.00. You will receive a targeted annual equity grant of $400,000 for fiscal year 2019 with a grant of $150,000 on August 6, 2018 and a grant of $250,000 on September 14, 2018 in accordance with the Stock-based Incentive Compensation Plan for Officers and Key Employees,

 

·                  Savings Plan (401k):  You remain eligible to participate in Carpenter’s retirement savings plan. Carpenter contributes 3% of your base pay andyou remain automatically enrolled for a 3% pre-tax employee contribution rate. However, you are eligible to modify the automatic contribution from 0% to 100% of your base pay of which Carpenter will match up to 6%.

 

·                  Health, Welfare and Retirement Benefits:  You remain eligible to participate in the employee benefit programs applicable to our salaried employees generally, including the Company’s health and welfare plans, as well as the defined contribution plan.  In addition, you remain eligible to participate in the Deferred Compensation Plan for Officers and Key Employees of Carpenter Technology Corporation.  Your annual vacation entitlement will be 5 weeks. Except as herein provided, or as may be hereafter approved by the Board or its Human Resources Committee, you will not be entitled to further compensation or benefits.

 

·                  Executive Severance Plan: Your employment by the Company is “at will” and may be terminated by

 

 

the Company or by you at any time.  However, if your employment terminates due to a termination by the Company without “cause” or a resignation by you with “good reason” (each, as defined in the attached Plan document), you will be entitled to receive the severance benefits in place for similarly situated employees. The Company has full discretion to change the program at any time, and included with this offer is the Severance Pay Plan for Executives of Carpenter.

 

·                  Change in Control Severance: You will be entitled to severance benefits in the event of a change in control, as described in the Change in Control Severance Plan. The Company has full discretion to change this program at any time. For avoidance of doubt, benefits under this section will be in lieu of, not in addition to, the severance benefits described in the Severance Pay Plan for Executives of Carpenter Technology Corporation.

 

·                  Intellectual Property, Confidentiality and Restrictive Covenants: In your capacity as an executive of the Company, you are exposed to the Company’s most sensitive and proprietary information and technology, and you will be provided with access to the Company’s most valuable and carefully cultivated business relationships.  Accordingly, your employment is conditioned upon your continued obligations under the Intellectual Property Agreement and Non-Competition Agreement.

 

You represent and warrant that there are no restrictions, agreements or understandings whatsoever that would prevent or make unlawful your execution of this letter, that would be inconsistent or in conflict with this letter or your obligations hereunder, or that would otherwise prevent, limit or impair your ability to be employed by the Company.  Your ownership of or transactions in securities of the Company will be subject to the Company’s insider trading policies and stock ownership guidelines from time to time effect.

 

Reimbursement by the Company of any expense will be subject to Company policies and practices in effect from time to time and will be further subject to the requirements of Treas. Reg 1/409A-3(i)(1)(iv)(A)(3), (4) and (5). Any payment of transfer of property to you will be subject to tax withholding to the extent required by applicable law.

 

This letter constitutes our entire agreement and understanding regarding the matters addressed herein, and merges and supersedes all prior or contemporaneous discussions, agreements, and understandings of every nature between us regarding these matters.  This letter is governed by, and enforced in accordance with, the laws of the Commonwealth of Pennsylvania, without regard to the application of the principles of conflicts of law.

 

To acknowledge your consent and agreement to with the foregoing, please execute and date this letter in the space provided below and return an executed copy to me.  This letter may be signed in multiple counterparts, each of which will be deemed an original, and all of which together will constitute a single instrument.

 

Congratulations.

 

 

Sincerely,

 

	
/s/   John Rice
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
John   Rice
    	
 
    	
 
    
	
VP,   Human Resources
    	
 
    	
 
    
	
Carpenter   Technology Corp.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
ACCEPTED:
    	
 
    	
DATE:
    
	
 
    	
 
    	
 
    
	
/s/   Timothy F. Lain
    	
 
    	
August 8,   2018
    
	
Name:   Timothy F. LainExhibit

SELECTA BIOSCIENCES, INC.
CONSULTING AGREEMENT 
(Omid Farokhzad, M.D.)
This Consulting Agreement dated as of May 30, 2018 (this “Agreement”), is made by and between Selecta Biosciences, Inc., a Delaware corporation (the “Company”), and Omid Farokhzad, M.D. (the “Consultant”).
WHEREAS, the Company desires to engage the Consultant to perform consulting services on behalf of the Company and the Consultant desires to perform such services on the terms and conditions hereinafter set forth.
NOW, THEREFORE, in consideration of the promises and the mutual covenants set forth herein the parties hereby agree as follows:
1.      Consulting Services.  
(a)    The Company hereby retains the Consultant and the Consultant hereby agrees to perform such consulting and advisory services as the Company may request and as set forth in Schedule A (the “Consulting Services”).   
(b)    The Consultant agrees to make himself available to render the Consulting Services, at such times and locations as may be mutually agreed, from time to time as requested by the Company.  Except as provided in Schedule A, the Consultant may deliver the Consulting Services over the telephone, in person or by written correspondence.  
(c)     The Consultant agrees to devote his best efforts to performing the Consulting Services. The Consultant shall comply with all rules, procedures and standards promulgated from time to time by the Company with regard to the Consultant’s access to and use of the Company’s property, information, equipment and facilities.
2.     Compensation.  The Company shall pay the Consultant a consulting fee as provided in Schedule A.  The Company will reimburse the Consultant for such reasonable business expenses as are incurred by the Consultant in the performance of Consulting Services for the Company.
3.     Independent Contractor.  In furnishing the Consulting Services, the Consultant understands that he will at all times be acting as an independent contractor of the Company and, as such, will not be an employee of the Company and will not by reason of this Agreement or by reason of his Consulting Services to the Company be entitled to participate in or to receive any benefit or right under any of the Company’s employee benefit or welfare plans.  The Consultant also will be responsible for paying all withholding and other taxes required by law to be paid as and when the same become due and payable.  Consultant shall not enter into any agreements or incur any obligations on behalf of the Company.

- 1 -

4.    Term.  The term of this Agreement will begin on April 1, 2018 and will end on March 31, 2019; provided, however, that the term may be extended by mutual agreement of the Company and the Consultant. The Company may terminate this Agreement at any time for any reason, without cause and without prior notice.
5.       Exceptions to this Agreement.
(a)    Certain Other Contracts.  The Company acknowledges that (I) the Consultant is the Chief Executive Officer of Seer Biosciences (“Seer”), (II) the Consultant is an unpaid member of the faculty of Harvard Medical School (“HMS”) and Brigham & Women’s Hospital (“BWH) (HMS, BWH and Seer referred to herein as the “Institutions”), and (III) the Consultant is now or may become a party to agreements with the Institutions and other third parties relating to the disclosure of information, the ownership of inventions, restrictions against competition and/or similar matters.  The Consultant represents and agrees that the execution, delivery and performance of this Agreement does not and will not conflict with any other agreement, policy or rule applicable to the Consultant.  The Consultant will not (i) disclose to the Company any information that he is required to keep secret pursuant to an existing confidentiality agreement with the Institutions or any other third party, (ii) use the funding, resources, facilities or inventions of the Institutions or any other third party to perform the Consulting Services, or (iii) perform the Consulting Services in any manner that would give the Institutions or any other third party rights to any intellectual property created in connection with such services.   
(b)    Prior Inventions.  The Consultant has informed the Company, in writing, of any and all Inventions in Field of Interest, which he claims as his own or otherwise intends to exclude from this Agreement because it was developed by him prior to the date of this Agreement.  The Consultant acknowledges that after execution of this Agreement he shall have no right to exclude any Inventions (as defined in Section 7) from this Agreement.  
6.    Confidential Information.    While providing the Consulting Services to the Company and thereafter, the Consultant shall not, directly or indirectly, use any Confidential Information (as defined below) other than pursuant to his provision of the Consulting Services by and for the benefit of the Company, or disclose to anyone outside of the Company any such Confidential Information.  The term “Confidential Information” as used throughout this Agreement shall mean all trade secrets, proprietary information and other data or information (and any tangible evidence, record or representation thereof), written or oral, whether prepared, conceived or developed by a consultant or employee of the Company (including the Consultant) or received by the Company from an outside source, which is in the possession of the Company (whether or not the property of the Company) and which is maintained in secrecy or confidence by the Company.  Without limiting the generality of the foregoing, Confidential Information shall include:
            (a)  any idea, improvement, invention, innovation, development, concept, technical data, design, formula, device, pattern, sequence, method, process, composition of matter, computer program or software, source code, object code, algorithm, model, diagram, flow chart, product specification or design, plan for a new or revised product, sample, 

- 2 -

compilation of information, or work in process, or parts thereof, and any and all revisions and improvements relating to any of the foregoing (in each case whether or not reduced to tangible form); and
(b)  the name of any customer, supplier, employee, prospective customer, sales agent, supplier or consultant, any sales plan, marketing material, plan or survey, business plan or opportunity, product or development plan or specification, business proposal, financial record, or business record or other record or information relating to the present or proposed business of the Company.
Notwithstanding the foregoing, the term Confidential Information shall not apply to information which the Company has voluntarily disclosed to the public without restriction or which has otherwise lawfully entered the public domain.
The Consultant acknowledges that the Company from time to time has in its possession information (including product and development plans and specifications) which represent information which is claimed by others to be proprietary and which the Company has agreed to keep confidential.  The Consultant agrees that all such information shall be Confidential Information for purposes of this Agreement.
The Consultant agrees that all originals and all copies of materials containing, representing, evidencing, recording, or constituting any Confidential Information, however and whenever produced (whether by the Consultant or others), shall be the sole property of the Company.
7.    Inventions. 
(a)    Certain Inventions Made by Others.  Subject to the Consultant’s obligations to the Institutions and other third parties, during the Term of this Agreement, the Consultant will use his best efforts (i) to disclose to the President of the Company, on a confidential basis, technology and product opportunities which come to the attention of the Consultant in the Field of Interest (as defined in Section 13(j)), and (ii) any invention, improvement, discovery, process, formula or method or other intellectual property relating to or useful in, the Field of Interest, whether or not patentable or copyrightable, and whether or not discovered or developed by Consultant.     
(b)    Inventions Made by the Consultant.  Subject to the Consultant’s obligations to the Institutions, Consultant agrees that all Confidential Information and all other discoveries, inventions, ideas, concepts, trademarks, service marks, logos, processes, products, formulas, computer programs or software, source codes, object codes, algorithms, machines, apparatuses, items of manufacture or composition of matter, or any new uses therefor or improvements thereon, or any new designs or modifications or configurations of any kind, or works of authorship of any kind, including, without limitation, compilations and derivative works, whether or not patentable or copyrightable, conceived, developed, reduced to practice or otherwise made by the Consultant during the Term of this Agreement, either alone or with others, and directly related to or arising out of:  (i) the Field of Interest; (ii) the Consulting Services; or 

- 3 -

(iii) Confidential Information of the Company, whether or not conceived, developed, reduced to practice or made on the Company’s premises (collectively, “Company Inventions”), and any and all services and products which embody, emulate or employ any such Company Invention or Confidential Information shall be the sole property of the Company and all copyrights, patents, patent rights, trademarks and reproduction rights to, and other proprietary rights in, each such Company Invention or Confidential Information, whether or not patentable or copyrightable, shall belong exclusively to the Company.  The Consultant agrees that all such Company Inventions shall constitute works made for hire under the copyright laws of the United States and hereby assigns and, to the extent any such assignment cannot be made at the present time, agrees to assign, to the Company any and all copyrights, patents and other proprietary rights he may have in any such Company Invention, together with the right to file and/or own wholly without restrictions applications for United States and foreign patents, trademark registration and copyright registration and any patent, or trademark or copyright registration issuing thereon.
8.    Consultant’s Obligation to Keep Records.  Consultant shall make and maintain adequate and current written records of all Company Inventions, and shall disclose all Company Inventions promptly, fully and in writing to the Company immediately upon development of the same and at any time upon request.
9.    Consultant’s Obligation to Cooperate.  The Consultant will, at any time during or after the term of this Agreement, upon request of the Company, execute all documents and perform all lawful acts which the Company considers necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement.  Without limiting the generality of the foregoing, the Consultant will assist the Company in any reasonable manner to obtain for its own benefit patents or copyrights in any and all countries with respect to all Company Inventions assigned pursuant to Section 7, and the Consultant will execute, when requested, patent and other applications and assignments thereof to the Company, or Persons (as defined in Section 13(j)) designated by it, and any other lawful documents deemed necessary by the Company to carry out the purposes of this Agreement, and the Consultant will further assist the Company in every way to enforce any patents and copyrights obtained, including testifying in any suit or proceeding involving any of said patents or copyrights or executing any documents deemed necessary by the Company, all without further consideration than provided for herein.  It is understood that reasonable out‐of‐pocket expenses of the Consultant’s assistance incurred at the request of the Company under this Section will be reimbursed by the Company.
10.    Noncompetition.  Subject to written waivers that may be provided by the Company upon request, which shall not be unreasonably withheld, the Consultant agrees that during the term of this Agreement and for a period of twelve months after the termination of this Agreement (the “Restricted Period”), the Consultant shall not directly or indirectly (i) provide any services in the Field of Interest to any Person other than the Company, (ii) become an owner, partner, shareholder, consultant, agent, employee or co-venturer of any Person that has committed, or intends to commit, significant resources to the Field of Interest.  Notwithstanding the foregoing, the Consultant may purchase as a passive investment up to one percent (1%) of any class or series of outstanding voting securities of any Person that has committed significant 

- 4 -

resources to the Field of Interest if such class or series is listed on a national or regional securities exchange or publicly traded in the “over-the-counter” market. 
11.    Nonsolicitation.  During the Restricted Period, the Consultant shall not (i) solicit, encourage, or take any other action which is intended to induce any employee of, or consultant to, the Company (or any other Person who may have been employed by, or may have been a consultant to, the Company during the Term) to terminate his or her employment or relationship with the Company in order to become employed by or otherwise perform services for any other Person or (ii) solicit, endeavor to entice away from the Company or otherwise interfere with the relationship of the Company with any Person who is, or was within the then-most recent 12 month period, a client or customer of the Company.
12.   Return of Property.  Upon termination of the Consultant’s engagement with the Company, or at any other time upon request of the Company, the Consultant shall return promptly any and all Confidential Information, including customer or prospective customer lists, other customer or prospective customer information or related materials, computer programs, software, electronic data, specifications, drawings, blueprints, medical devices, samples, reproductions, sketches, notes, notebooks, memoranda, reports, records, proposals, business plans, or copies of them, other documents or materials, tools, equipment, or other property belonging to the Company or its customers which the Consultant may then possess or have under his control.  The Consultant further agrees that upon termination of his engagement he shall not take with him any documents or data in any form or of any description containing or pertaining to Confidential Information or any Company Inventions.
13.    Miscellaneous.  
(a)     Entire Agreement.  This Agreement and the documents referred to herein constitute the entire agreement among the parties with respect to the Consulting Services and supersede all other prior agreements and understandings, both written and oral, between the parties with respect to such Consulting Services.  
(b)    Assignment.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.  This Agreement is not intended to confer upon any person other than the parties hereto any rights or remedies hereunder, except as otherwise expressly provided herein and shall not be assignable by operation of law or otherwise.
(c)    Amendments and Supplements.  This Agreement may not be altered, changed or amended, except by an instrument in writing signed by the parties hereto.
(d)    No Waiver.  The terms and conditions of this Agreement may be waived only by a written instrument signed by the party waiving compliance.  The failure of any party hereto to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement or any part hereof or the right of such party thereafter to enforce each and every such 

- 5 -

provision.  No waiver of any breach of or non-compliance with this Agreement shall be held to be a waiver of any other or subsequent breach or non-compliance.  
(e)    Governing Law.  This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of The Commonwealth of Massachusetts, without regard to its principles of conflicts of laws.
(f)    Notice.  All notices and other communications hereunder shall be in writing and shall be deemed given if delivered by hand, sent by facsimile transmission with confirmation of receipt, sent via a reputable overnight courier service with confirmation of receipt requested, or mailed by registered or certified mail (postage prepaid and return receipt requested) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice), and shall be deemed given on the date on which delivered by hand or otherwise on the date of receipt as confirmed:
To the Company:
Selecta Biosciences, Inc.
480 Arsenal Way
Watertown, MA 02472
Attention: General Counsel

To the Consultant:
Omid Farokhzad, M.D. 
15 Laura Road
Waban, MA 02468 

(g)     Remedies.  The Consultant recognizes that money damages alone would not adequately compensate the Company in the event of breach by the Consultant of this Agreement, and the Consultant therefore agrees that, in addition to all other remedies available to the Company at law, in equity or otherwise, the Company shall be entitled to injunctive relief for the enforcement hereof.  All rights and remedies hereunder are cumulative and are in addition to and not exclusive of any other rights and remedies available at law, in equity, by agreement or otherwise.
(h)    Survival; Validity.  Notwithstanding the termination of the Consultant’s relationship with the Company (whether pursuant to Section 4 or otherwise), the Consultant’s covenants and obligations set forth in Sections 6, 7, 9, 10, 11 and 12 shall remain in effect and be fully enforceable in accordance with the provisions thereof.  In the event that any provision of this Agreement shall be determined to be unenforceable by reason of its extension for too great a period of time or over too large a geographic area or over too great a range of activities, it shall be interpreted to extend only over the maximum period of time, geographic area or range of activities as to which it may be enforceable.  If, after application of the preceding sentence, any provision of this Agreement shall be determined to be invalid, illegal or otherwise unenforceable by a court of competent jurisdiction, the validity, legality and enforceability of the other 

- 6 -

provisions of this Agreement shall not be affected thereby.  Except as otherwise provided in this Section 13(h), any invalid, illegal or unenforceable provision of this Agreement shall be severable, and after any such severance, all other provisions hereof shall remain in full force and effect.
(i)    Construction.  A reference to a Section or a Schedule shall mean a Section in or Schedule to this Agreement unless otherwise expressly stated.  The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this Agreement which shall be considered as a whole.  The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.”  Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa.
(j)    Certain Definitions. 
 “Field of Interest” shall mean immunomodulatory nanoparticles and tolerogenic dendritic cells for prophylactic and therapeutic applications.
“Person” shall mean an individual, a corporation, an association, a partnership, an estate, a trust and any other entity or organization.
(k)    Counterparts.  This Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same Agreement.
*****

- 7 -

IN WITNESS WHEREOF, the parties have caused this Consulting Agreement to be executed as an agreement under seal as of the date first written above.
SELECTA BIOSCIENCES, INC.

By: /s/ Werner Cautreels   ______________ 
Name:    Werner Cautreels, Ph.D. 
Title: President and Chief Executive Officer

CONSULTANT:

/s/ Omid Farokhzad                 
                            Omid Farokhzad, M.D.

- 8 -

Schedule A 
1.    Description of Consulting Services.
The Consultant shall provide such consulting services as the Company’s management team or Board of Directors (the “Board”) reasonably requests in connection with the Company’s business.  
2.    Compensation.
The Company shall grant the Consultant an option to purchase 95,000 shares of the Company’s common stock (the “Option”), subject to approval by the Company’s Board of Directors. The Option shall be subject to the terms and conditions of the 2016 Incentive Award Plan (the “2016 Plan”) and a stock option agreement in substantially the form attached to this Schedule A.

- 9 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]